TrialClinical and translational science2024

MB09, a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects.

Monika Tomaszewska-Kiecana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.